Top

23-04-2024 | Ovarian Cancer | Original Article

Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer

Authors: In Hee Lee, Soo Jung Lee, Juhyung Kim, Yoon Hee Lee, Gun Oh Chong, Jong Mi Kim, Juhun Lee, Nan Young Lee, Seo Young Park, Dea Gy Hong, Yee Soo Chae

Published in: Cancer Chemotherapy and Pharmacology

Abstract

Objective

BRCA1/2 are integral to the DNA repair mechanism and their germline pathogenic variants (gBRCA) result in a high risk for developing breast and ovarian cancer. Patients with gBRCA mutations showed increased sensitivity to DNA cross-linking agent but might have increased treatment-related toxicities. Thus, we hypothesized that gBRCA mutation ovarian cancer patients who underwent platinum-based chemotherapy might be at higher risk of developing chemotherapy-induced hematologic toxicity.

Methods

This study enrolled 160 patients with ovarian cancer who received frontline platinum-based chemotherapy between 2011 and 2019 in Kyungpook National University Chilgok Hospital. Incidence rate and severity of chemotherapy-induced hematologic toxicity (neutropenia, anemia, thrombocytopenia) was compared for BRCA mutation and wild patients.

Results

160 women, including 62 BRCA1/2 (38 BRCA1, and 25 BRCA2) mutation group, and 98 noncarriers, were analyzed. A higher frequency of G2 anemia was noted in the BRCA -mutant group (22% vs. 1%, p = 0.07). Furthermore, G3 anemia was significantly common among BRCA group (12.9% vs. 3%, p = 0.02). In the subgroup analysis according to BRCA1/2 status, BRCA1 mutated patients showed a significantly higher frequency of G1 anemia than BRCA2 (89% vs. 60%, p = 0.01). In terms of neutropenia and thrombocytopenia, BRCA mutated patients and noncarriers had similar hematologic toxicity.

Conclusion

Germline BRCA mutations were associated with a higher frequency of G2/3 anemia in ovarian cancer patients who underwent first-line platinum-based chemotherapy. Moreover, the BRCA1 mutation appeared to be more strongly associated with the incidence of chemotherapy-induced anemia. Our findings warrant further investigation in larger, prospective studies to confirm these current findings and determine whether preventive interventions may be necessary.

Banerjee S, Kaye SB (2013) New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res 19(5):961–968. https://doi.org/10.1158/1078-0432.Ccr-12-2243CrossRefPubMed

Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN (2010) Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 8(5):562–594. https://doi.org/10.6004/jnccn.2010.0043CrossRefPubMed

Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4(10):814–819. https://doi.org/10.1038/nrc1457CrossRefPubMed

Nielsen FC, van Overeem Hansen T, Sorensen CS (2016) Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer 16(9):599–612. https://doi.org/10.1038/nrc.2016.72CrossRefPubMed

Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8(3):193–204. https://doi.org/10.1038/nrc2342CrossRefPubMed

Negrini S, Gorgoulis VG, Halazonetis TD (2010) Genomic instability–an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11(3):220–228. https://doi.org/10.1038/nrm2858CrossRefPubMed

Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O’Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Perez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ, Investigators PE-OG- (2019) Niraparib in patients with newly diagnosed Advanced Ovarian Cancer. N Engl J Med 381(25):2391–2402. https://doi.org/10.1056/NEJMoa1910962CrossRefPubMed

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, Gonzalez-Martin A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P (2018) Maintenance Olaparib in patients with newly diagnosed Advanced Ovarian Cancer. N Engl J Med 379(26):2495–2505. https://doi.org/10.1056/NEJMoa1810858CrossRefPubMed

Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, Fujiwara K, Vergote I, Colombo N, Maenpaa J, Selle F, Sehouli J, Lorusso D, Guerra Alia EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marme F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P, Investigators P- (2019) Olaparib plus Bevacizumab as First-Line maintenance in Ovarian Cancer. N Engl J Med 381(25):2416–2428. https://doi.org/10.1056/NEJMoa1911361CrossRefPubMed

10.

Orsi G, Di Marco M, Cavaliere A, Niger M, Bozzarelli S, Giordano G, Noventa S, Rapposelli IG, Garajova I, Tortora G, Rodriquenz MG, Bittoni A, Penzo E, De Lorenzo S, Peretti U, Paratore C, Bernardini I, Mosconi S, Spallanzani A, Macchini M, Tamburini E, Bencardino K, Giommoni E, Scartozzi M, Forti L, Valente MM, Militello AM, Cascinu S, Milella M, Reni M (2021) Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey. ESMO Open 6(5):100238. https://doi.org/10.1016/j.esmoop.2021.100238CrossRefPubMedPubMedCentral

11.

Byrski T, Dent R, Blecharz P, Foszczynska-Kloda M, Gronwald J, Huzarski T, Cybulski C, Marczyk E, Chrzan R, Eisen A, Lubinski J, Narod SA (2012) Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 14(4):R110. https://doi.org/10.1186/bcr3231CrossRefPubMedPubMedCentral

12.

Deshpande M, Paniza T, Jalloul N, Nanjangud G, Twarowski J, Koren A, Zaninovic N, Zhan Q, Chadalavada K, Malkova A, Khiabanian H, Madireddy A, Rosenwaks Z, Gerhardt J (2022) Error-prone repair of stalled replication forks drives mutagenesis and loss of heterozygosity in haploinsufficient BRCA1 cells. Mol Cell 82(20):3781–3793e3787. https://doi.org/10.1016/j.molcel.2022.08.017CrossRefPubMed

13.

Mgbemena VE, Signer RAJ, Wijayatunge R, Laxson T, Morrison SJ, Ross TS (2017) Distinct Brca1 mutations differentially reduce hematopoietic stem cell function. Cell Rep 18(4):947–960. https://doi.org/10.1016/j.celrep.2016.12.075CrossRefPubMedPubMedCentral

14.

Sedic M, Skibinski A, Brown N, Gallardo M, Mulligan P, Martinez P, Keller PJ, Glover E, Richardson AL, Cowan J, Toland AE, Ravichandran K, Riethman H, Naber SP, Näär AM, Blasco MA, Hinds PW, Kuperwasser C (2015) Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence. Nat Commun 6:7505. https://doi.org/10.1038/ncomms8505CrossRefPubMed

15.

Pathania S, Bade S, Le Guillou M, Burke K, Reed R, Bowman-Colin C, Su Y, Ting DT, Polyak K, Richardson AL, Feunteun J, Garber JE, Livingston DM (2014) BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat Commun 5:5496. https://doi.org/10.1038/ncomms6496CrossRefPubMed

16.

Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH (2011) Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci USA 108(43):17773–17778. https://doi.org/10.1073/pnas.1110969108CrossRefPubMedPubMedCentral

17.

Kottemann MC, Smogorzewska A (2013) Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature 493(7432):356–363. https://doi.org/10.1038/nature11863CrossRefPubMedPubMedCentral

18.

Hu-Heimgartner K, Lang N, Ayme A, Ming C, Combes JD, Chappuis VN, Vazquez C, Friedlaender A, Vuilleumier A, Bodmer A, Viassolo V, Sandoval JL, Chappuis PO, Labidi-Galy SI (2023) Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature. Fam Cancer 22(3):283–289. https://doi.org/10.1007/s10689-023-00331-6CrossRefPubMedPubMedCentral

19.

Kwon BS, Byun JM, Lee HJ, Jeong DH, Lee TH, Shin KH, Suh DS, Kim KH (2019) Clinical and genetic characteristics of BRCA1/2 mutation in Korean ovarian Cancer patients: a Multicenter Study and Literature Review. Cancer Res Treat 51(3):941–950. https://doi.org/10.4143/crt.2018.312CrossRefPubMed

20.

Kang E, Kim SW (2013) The Korean hereditary breast cancer study: review and future perspectives. J Breast Cancer 16(3):245–253. https://doi.org/10.4048/jbc.2013.16.3.245CrossRefPubMedPubMedCentral

21.

Weitzner O, Yagur Y, Kadan Y, Beiner ME, Fishman A, Ben Ezry E, Amitai Komem D, Helpman L (2019) Chemotherapy toxicity in BRCA mutation carriers undergoing first-line platinum-based chemotherapy. Oncologist 24(12):e1471–e1475. https://doi.org/10.1634/theoncologist.2019-0272CrossRefPubMedPubMedCentral

22.

Kotsopoulos J, Willows K, Trat S, Kim RH, Volenik A, Sun P, Narod SA, Boyd J, May T (2018) BRCA mutation status is not Associated with increased hematologic toxicity among patients undergoing platinum-based chemotherapy for ovarian Cancer. Int J Gynecol cancer: Official J Int Gynecol Cancer Soc 28(1):69–76. https://doi.org/10.1097/igc.0000000000001144CrossRef

23.

Tomao F, Musacchio L, Di Mauro F, Boccia SM, Di Donato V, Giancotti A, Perniola G, Palaia I, Muzii L, Benedetti Panici P (2019) Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients? Gynecol Oncol 154(1):138–143. https://doi.org/10.1016/j.ygyno.2019.04.009CrossRefPubMed

24.

Furlanetto J, Mobus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Lubbe K, Untch M, Salat C, Huober J, Klare P, Schmutzler R, Couch FJ, Lederer B, Gerber B, Zahm DM, Bauerfeind I, Nekljudova V, Hanusch C, Jackisch C, Link T, Hahnen E, Loibl S, Fasching PA (2021) Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. Eur J cancer (Oxford England: 1990) 145:44–52. https://doi.org/10.1016/j.ejca.2020.12.007CrossRef

Title: Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer
Authors: In Hee Lee
Soo Jung Lee
Juhyung Kim
Yoon Hee Lee
Gun Oh Chong
Jong Mi Kim
Juhun Lee
Nan Young Lee
Seo Young Park
Dea Gy Hong
Yee Soo Chae
Publication date: 23-04-2024
Publisher: Springer Berlin Heidelberg
Keywords: Ovarian Cancer
Ovarian Cancer
Cytostatic Therapy
Anemia
Neutropenia
Thrombocytopenia
Published in: Cancer Chemotherapy and Pharmacology
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-024-04670-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine